Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

International Stem Cell Corp. (ISCO) Proclaims Remarkable Success Of In Vivo Parkinson's Disease Study

|Includes: International Stem Cell Corp. (ISCO)

International Stem Cell Corp., a company specializing in the therapeutic applications of human parthenogenetic stem cells (hpSCs), reported positive 12-week results from its pre-clinical in vivo Parkinson's disease study. This behavioral study's primary objective was to demonstrate the therapeutic benefits of neuronal cells derived from a human parthenogenetic stem cell line in a rat model of Parkinson's disease (PD).

A common neurodegenerative disorder caused by a progressive degeneration of dopamine-producing neurons resulting in gradual dysfunction of the motor system, PD can eventually lead to death. Pharmacological treatments can be useful in the early stages of the disease, but the continuous use of pro-dopaminergic medication in time becomes ineffective and can even worsen some of the motor symptoms.

In contrast, ISCO's proprietary technology is based on a homogeneous population of neuronal cells (NCs) derived from homozygous hpSCs through a scalable and efficient method. These parthenogenetically derived NCs are cryopreservable and can become neurons once they are implanted into the brain. They hold tremendous therapeutic potential not only because they can differentiate into dopamine-producing neurons, but also because they could provide a level of protection to existing neurons affected by the disease.

ISCO utilized a well-established and validated model of PD for its pre-clinical study. The experimental rats with unilateral dopamine (6-OHDA) lesions survived the inoculation of cells into the brain and signs of improvement in rotational behavior of these animals were obvious. Correlational analysis of rotation intensity confirmed a difference between the drug effects in the control group vs. experimental (transplanted) group of animals. Interim results demonstrate that just a single injection of hpSC-derived neuronal cells can lead to a notable slowdown in the progression of the disease.

"This is a very important result for our pre-clinical Parkinson's program," Dr. Ruslan Semechkin, Vice President - head of R&D, commented. "The initial in vivo results are very encouraging and show the therapeutic promise of hpSC-derived neuronal cells in the treatment of individuals with Parkinson's disease. Results from this behavioral study will be presented and discussed together with the results of non-human primate study before the end of the first quarter of 2013″

Let more information on International Stem Cell Corp., visit internationalstemcell.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net